Catalogo Articoli (Spogli Riviste)

HELP
ATTENZIONE: attualmente gli articoli Current Contents (fonte ISI) a partire dall'anno 2002 sono consultabili sulla Risorsa On-Line

Le informazioni sugli articoli di fonte ISI sono coperte da copyright

La ricerca find articoli where soggetti phrase all words 'pamidronate' sort by level,fasc_key/DESCEND, pagina_ini_num/ASCEND ha restituito 509 riferimenti
Si mostrano 100 riferimenti a partire da 1
Selezionare un intervallo

Per ulteriori informazioni selezionare i riferimenti di interesse.

    1. Suri, S; Monkkonen, J; Taskinen, M; Pesonen, J; Blank, MA; Phipps, RJ; Rogers, MJ
      Nitrogen-containing bisphosphonates induce apoptosis of Caco-2 cells in vitro by inhibiting the mevalonate pathway: A model of bisphosphonate-inducedgastrointestinal toxicity

      BONE
    2. Smith, SC; Koh, WJ
      Palliative radiation therapy for gynaecological malignancies

      BEST PRACTICE & RESEARCH IN CLINICAL OBSTETRICS & GYNAECOLOGY
    3. Samson, D; Singer, CRJ
      Multiple myeloma

      CLINICAL MEDICINE
    4. Joshua, D
      Bone disease in multiple myeloma: new markers, new treatments

      INTERNAL MEDICINE JOURNAL
    5. Morris, TCM; Ranaghan, L; Morrison, J
      Phase II trial of clarithromycin and pamidronate therapy in myeloma

      MEDICAL ONCOLOGY
    6. Mishra, A; Wong, L; Jonklaas, J
      Prolonged, symptomatic hypocalcemia with pamidronate administration and subclinical hypoparathyroidism

      ENDOCRINE
    7. Maenpaa, H; Savolainen, A; Lehto, MUK; Belt, EA
      Multiple stress fractures in a young girl with chronic idiopathic arthritis. Extended case report

      JOINT BONE SPINE
    8. Chevrel, G; Meunier, PJ
      Osteogenesis imperfecta: lifelong management is imperative and feasible

      JOINT BONE SPINE
    9. Coyte, PC; Dobrow, MJ; Broadfield, L
      Incremental cost analysis of ambulatory clinic and home-based intravenous therapy for patients with multiple myeloma

      PHARMACOECONOMICS
    10. Parisi, MS; Oliveri, MB; Acotto, CG; Mautalen, CA
      Bone mineral density response to long-term bisphosphonate therapy in fibrous dysplasia

      JOURNAL OF CLINICAL DENSITOMETRY
    11. Davidson, TG
      Conventional treatment of hypercalcemia of malignancy

      AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY
    12. Berenson, JR
      Advances in the biology and treatment of myeloma bone disease

      AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY
    13. Berenson, JR; Vescio, RA; Rosen, LS; VonTeichert, JM; Woo, M; Swift, R; Savage, A; Givant, E; Hupkes, M; Harvey, H; Lipton, A
      A phase I dose-ranging trial of monthly infusions of zoledronic acid for the treatment of osteolytic bone metastases

      CLINICAL CANCER RESEARCH
    14. Reale, C; Turkiewicz, AM; Reale, CA
      Antalgic treatment of pain associated with bone metastases

      CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
    15. Smith, R
      Severe osteogenesis imperfecta: new therapeutic options? Aminobisphosphonates offer promise, while bone marrow transplants remain experimental

      BRITISH MEDICAL JOURNAL
    16. Vehmanen, L; Saarto, T; Elomaa, I; Makela, P; Valimaki, M; Blomqvist, C
      Long-term impact of chemotherapy-induced ovarian failure on bone mineral density (BMD) in premenopausal breast cancer patients. The effect of adjuvant clodronate treatment

      EUROPEAN JOURNAL OF CANCER
    17. Suzuma, T; Sakurai, T; Yoshimura, G; Umemura, T; Tamaki, T; Yoshimasu, T; Naito, Y
      Pamidronate-induced remission of pain associated with hypertrophic pulmonary osteoarthropathy in chemoendocrine therapy-refractory inoperable metastatic breast carcinoma

      ANTI-CANCER DRUGS
    18. Sonnemann, J; Eckervogt, V; Truckenbrod, B; Boos, J; Winkelmann, W; van Valen, F
      The bisphosphonate pamidronate is a potent inhibitor of human osteosarcomacell growth in vitro

      ANTI-CANCER DRUGS
    19. Lamy, O; Jenzer-Closuit, A; Burckhardt, P
      Hypercalcaemia of malignancy: an undiagnosed and undertreated disease

      JOURNAL OF INTERNAL MEDICINE
    20. Castel, LD; Bajwa, K; Markle, JP; Timbie, JW; Zacker, C; Schulman, KA
      A microcosting analysis of zoledronic acid and pamidronate therapy in patients with metastatic bone disease

      SUPPORTIVE CARE IN CANCER
    21. Beusterien, KM; Hill, MC; Ackerman, SJ; Zacker, C
      The impact of pamidronate on inpatient and outpatient services among metastatic breast cancer patients

      SUPPORTIVE CARE IN CANCER
    22. Bayne, MC; Illidge, TM
      Hypercalcaemia, parathyroid hormone-related protein and malignancy

      CLINICAL ONCOLOGY
    23. Guillot, M; Eckart, P; Desrosieres, H; Amiour, M; Al-Jazayri, Z
      Osteogenesis imperfecta: a new therapeutic approach with biphosphonates. Acase report.

      ARCHIVES DE PEDIATRIE
    24. Jagdev, SP; Purohit, OP; Heatley, S; Herling, C; Coleman, RE
      Comparison of the effects of intravenous pamidronate and oral clodronate on symptoms and bone resorption in patients with metastatic bone disease

      ANNALS OF ONCOLOGY
    25. Berenson, JR
      Painful osteoblastic metastases: The role of nuclear medicine - The Silberstein article reviewed

      ONCOLOGY-NEW YORK
    26. Stuckey, BGA; Lim, EM; Kent, GN; Ward, LC; Gutteridge, DH
      Bisphosphonate therapy for Paget's disease in a patient with hypoparathyroidism: Profound hypocalcemia, rapid response, and prolonged remission

      JOURNAL OF BONE AND MINERAL RESEARCH
    27. Fleisch, H
      Can bisphosphonates be given to patients with fractures?

      JOURNAL OF BONE AND MINERAL RESEARCH
    28. Wilkinson, JM; Stockley, I; Peel, NFA; Hamer, AJ; Elson, RA; Barrington, NA; Eastell, R
      Effect of pamidronate in preventing local bone loss after total hip arthroplasty: A randomized, double-blind, controlled trial

      JOURNAL OF BONE AND MINERAL RESEARCH
    29. Boutsen, Y; Jamart, J; Esselinckx, W; Devogelaer, JP
      Primary prevention of gluccocorticoid-induced osteoporosis with intravenous pamidronate and calcium: A prospective controlled 1-year study comparing a single infusion, an infusion given once every 3 months, and calcium alone

      JOURNAL OF BONE AND MINERAL RESEARCH
    30. Go, T
      Low-dose oral etidronate therapy for immobilization hypercalcaemia associated with Guillain-Barre syndrome

      ACTA PAEDIATRICA
    31. Ali, SM; Esteva, FJ; Hortobagyi, G; Harvey, H; Seaman, J; Knight, R; Costa, L; Lipton, A
      Safety and efficacy of bisphosphonates beyond 24 months in cancer patients

      JOURNAL OF CLINICAL ONCOLOGY
    32. Saarto, T; Blomqvist, C; Virkkunen, P; Elomaa, I
      Adjuvant clodronate treatment does not reduce the frequency of skeletal metastases in node-positive breast cancer patients: 5-year results of a randomized controlled trial

      JOURNAL OF CLINICAL ONCOLOGY
    33. Quattrocchi, O; Frisardi, L; Iglesias, M; Noya, M; Caputto, M; Ferraris, D; Siliprandi, D; Piccinni, E
      Ion exchange chromatographic determination of olpadronate, phosphate, phosphite, chloride and methanesulfonic acid

      JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS
    34. Van Offel, JF; Schuerwegh, AJ; Bridts, CH; Bracke, PG; Stevens, WJ; De Clerck, LS
      Influence of cyclic intravenous pamidronate on proinflammatory monocytic cytokine profiles and bone density in rheumatoid arthritis treated with low dose prednisolone and methotrexate

      CLINICAL AND EXPERIMENTAL RHEUMATOLOGY
    35. Raiman, J; Niemi, R; Vepsalainen, J; Yritys, K; Jarvinen, T; Monkkonen, J
      Effects of calcium and lipophilicity on transport of clodronate and its esters through Caco-2 cells

      INTERNATIONAL JOURNAL OF PHARMACEUTICS
    36. Inaoka, T; Shuke, N; Sato, J; Ishikawa, Y; Takahashi, K; Aburano, T; Makita, Y
      Scintigraphic evaluation of pamidronate and corticosteroid therapy in a patient with progressive diaphyseal dysplasia (Camurati-Engelmann disease)

      CLINICAL NUCLEAR MEDICINE
    37. Gonzalez, E; Pavia, C; Ros, J; Villaronga, M; Valls, C; Escola, J
      Efficacy of low dose schedule pamidronate infusion in children with osteogenesis imperfects

      JOURNAL OF PEDIATRIC ENDOCRINOLOGY & METABOLISM
    38. Zumkeller, W; Jassoy, A; Lebek, S; Nagel, M
      Clinical, endocrinological and radiological features in a child with McCune-Albright syndrome and pituitary adenoma

      JOURNAL OF PEDIATRIC ENDOCRINOLOGY & METABOLISM
    39. Maksymowych, WP; Aaron, SL; Russell, AS
      Treatment of refractory symphysitis pubis with intravenous pamidronate

      JOURNAL OF RHEUMATOLOGY
    40. Maksymowych, WP; Lambert, R; Jhangri, GS; Leclercq, S; Chiu, P; Wong, B; Aaron, S; Russell, AS
      Clinical and radiological amelioration of refractory peripheral spondyloarthritis by pulse intravenous pamidronate therapy

      JOURNAL OF RHEUMATOLOGY
    41. Diel, IJ
      Prognostic factors for skeletal relapse in breast cancer

      CANCER TREATMENT REVIEWS
    42. Coleman, RE
      Metastatic bone disease: clinical features, pathophysiology and treatment strategies

      CANCER TREATMENT REVIEWS
    43. Lipton, A; Costa, L; Ali, SM; Demers, LM
      Bone markers in the management of metastatic bone disease

      CANCER TREATMENT REVIEWS
    44. Bonabello, A; Galmozzi, MR; Bruzzese, T; Zara, GP
      Analgesic effect of bisphosphonates in mice

      PAIN
    45. Tomiska, M; Adam, Z; Prokes, B; Dusek, L; Hajek, R; Vorlicek, J
      Bone mineral density in multiple myeloma patients after intravenous clodronate therapy

      ACTA MEDICA AUSTRIACA
    46. Schmid, I; Stachel, D; Schon, C; Bauer, M; Haas, RJ
      Pamidronate and calcitonin as therapy of acute cancer-related hypercalcemia in children

      KLINISCHE PADIATRIE
    47. Guay, DRR
      Adjunctive agents in the management of chronic pain

      PHARMACOTHERAPY
    48. Groff, L; Zecca, E; De Conno, F; Brunelli, C; Boffi, R; Panzeri, C; Cazzaniga, M; Ripamonti, C
      The role of disodium pamidronate in the management of bone pain due to malignancy

      PALLIATIVE MEDICINE
    49. Lortholary, A
      Tumor-induced hypercalcemia. A review of the treatment by bisphosphonates

      REVUE DE MEDECINE INTERNE
    50. Camacho, NP; Raggio, CL; Doty, SB; Root, L; Zraick, V; Ilg, WA; Toledano, TR; Boskey, AL
      A controlled study of the effects of alendronate in a growing mouse model of osteogenesis imperfecta

      CALCIFIED TISSUE INTERNATIONAL
    51. Terpos, E; Palermos, J; Viniou, N; Vaiopoulos, G; Meletis, J; Yataganas, X
      Pamidronate increases markers of bone formation in patients with multiple myeloma in plateau phase under interferon-alpha treatment

      CALCIFIED TISSUE INTERNATIONAL
    52. Hirabayashi, H; Takahashi, T; Fujisaki, J; Masunaga, T; Sato, S; Hiroi, J; Tokunaga, Y; Kimura, S; Hata, T
      Bone-specific delivery and sustained release of diclofenac, a non-steroidal anti-inflammatory drug, via bisphosphonic prodrug based on the Osteotropic Drug Delivery System (ODDS)

      JOURNAL OF CONTROLLED RELEASE
    53. Carrasquillo, JA; Whatley, M; Dyer, V; Figg, WD; Dahut, W
      Alendronate does not interfere with Tc-99m-methylene diphosphonate bone scanning

      JOURNAL OF NUCLEAR MEDICINE
    54. Takahashi, R; Shimazaki, C; Inaba, T; Okano, A; Hatsuse, M; Okamoto, A; Hirai, H; Ashihara, E; Nakagawa, M
      A newly developed bisphosphonate, YM529, is a potent apoptosis inducer of human myeloma cells

      LEUKEMIA RESEARCH
    55. Tu, SM; Millikan, RE; Mengistu, B; Delpassand, ES; Amato, RJ; Pagliaro, LC; Daliani, D; Papandreou, CN; Smith, TL; Kim, J; Podoloff, DA; Logothetis, CJ
      Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: a randomised phase II trial

      LANCET
    56. Mundy, G
      Preclinical models of bone metastases

      SEMINARS IN ONCOLOGY
    57. Roodman, GD
      Studies in Paget's disease and their relevance to oncology

      SEMINARS IN ONCOLOGY
    58. LoRusso, P
      Analysis of skeletal-related events in breast cancer and response to therapy

      SEMINARS IN ONCOLOGY
    59. Janjan, N
      Bone metastases: Approaches to management

      SEMINARS IN ONCOLOGY
    60. Coleman, RE
      Should bisphosphonates be the treatment of choice for metastatic bone disease?

      SEMINARS IN ONCOLOGY
    61. Body, JJ
      Dosing regimens and main adverse events of bisphosphonates

      SEMINARS IN ONCOLOGY
    62. Lipton, A; Costa, L; Ali, S; Demers, L
      Use of markers of bone turnover for monitoring bone metastases and the response to therapy

      SEMINARS IN ONCOLOGY
    63. Perez, EA
      Metastatic bone disease in breast cancer: The patient's perspective

      SEMINARS IN ONCOLOGY
    64. Hillner, BE
      Pharmacoeconomic issues in bisphosphonate treatment of metastatic bone disease

      SEMINARS IN ONCOLOGY
    65. Van Poznak, C
      How are bisphosphonates used today in breast cancer clinical practice?

      SEMINARS IN ONCOLOGY
    66. Diel, IJ
      Bisphosphonates in the prevention of bone metastases: Current evidence

      SEMINARS IN ONCOLOGY
    67. Paterson, AHG
      Adjuvant bisphosphonate therapy: The future

      SEMINARS IN ONCOLOGY
    68. Theriault, RL; Hortobagyi, GN
      The evolving role of bisphosphonates

      SEMINARS IN ONCOLOGY
    69. Hortobagyi, GN
      Unmet needs in metastatic bone disease and its complications: Is progress possible?

      SEMINARS IN ONCOLOGY
    70. Coleman, RE; Seaman, JJ
      The role of zoledronic acid in cancer: Clinical studies in the treatment and prevention of bone metastases

      SEMINARS IN ONCOLOGY
    71. Major, PP; Coleman, RE
      Zoledronic acid in the treatment of hypercalcemia of malignancy: Results of the international clinical development program

      SEMINARS IN ONCOLOGY
    72. Berenson, JR
      Zoledronic acid in cancer patients with bone metastases: Results of phase I and II trials

      SEMINARS IN ONCOLOGY
    73. Mundy, GR; Yoneda, T; Hiraga, T
      Preclinical studies with zoledronic acid and other bisphosphonates: Impacton the bone microenvironment

      SEMINARS IN ONCOLOGY
    74. Fleisch, H
      Zoledronic acid: An evolving role in the treatment of cancer patients withbone disease

      SEMINARS IN ONCOLOGY
    75. Braun, J; Sieper, J
      Osteoporosis due to steroid therapy

      ORTHOPADE
    76. Haworth, CS; Selby, PL; Adams, JE; Mawer, EB; Horrocks, AW; Webb, AK
      Effect of intravenous pamidronate on bone mineral density in adults with cystic fibrosis

      THORAX
    77. Berenson, JR
      New advances in the biology and treatment of myeloma bone disease

      SEMINARS IN HEMATOLOGY
    78. Sekhar, RV; Culbert, S; Hoots, WK; Klein, MJ; Zietz, H; Vassilopoulou-Sellin, R
      Severe osteopenia in a young boy with Kostmann's congenital neutropenia treated with granulocyte colony-stimulating factor: Suggested therapeutic approach

      PEDIATRICS
    79. Smith, MR; McGovern, FJ; Zietman, AL; Fallon, MA; Hayden, DL; Schoenfeld, DA; Kantoff, PW; Finkelstein, JS
      Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer.

      NEW ENGLAND JOURNAL OF MEDICINE
    80. Fassi, J; Plantalech, L
      Vertebral osteoporosis due to high doses of corticoids and cyclosporine ina patient with Still disease.

      MEDICINA-BUENOS AIRES
    81. Berruti, A; Dogliotti, L; Tucci, M; Tarabuzzi, R; Fontana, D; Angeli, A
      Metabolic bone disease induced by prostate cancer: Rationale for the use of bisphosphonates

      JOURNAL OF UROLOGY
    82. Heidenreich, A; Hofmann, R; Engelmann, UH
      The use of bisphosphonate for the palliative treatment of painful bone metastasis due to hormone refractory prostate cancer

      JOURNAL OF UROLOGY
    83. Keijser, LCM; Van Tienen, TG; Schreuder, HWB; Lemmens, JAM; Pruszczynski, M; Veth, RPH
      Fibrous dysplasia of bone: Management and outcome of 20 cases

      JOURNAL OF SURGICAL ONCOLOGY
    84. Kato, Y; Tanaka, Y; Miyagawa, F; Yamashita, S; Minato, N
      Targeting of tumor cells for human gamma delta T cells by nonpeptide antigens

      JOURNAL OF IMMUNOLOGY
    85. Biermasz, NR; Hamdy, NAT; Janssen, YJH; Roelfsema, F
      Additional beneficial effects of alendronate in growth hormone (GH)-deficient adults with osteoporosis receiving long-term recombinant human GH replacement therapy: A randomized controlled trial

      JOURNAL OF CLINICAL ENDOCRINOLOGY AND METABOLISM
    86. Macedo, G; Azevedo, F; Ribeiro, T
      Ulcerative esophagitis caused by etidronate

      GASTROINTESTINAL ENDOSCOPY
    87. Jude, EB; Selby, PL; Burgess, J; Lilleystone, P; Mawer, EB; Page, SR; Donohoe, M; Foster, AVM; Edmonds, ME; Boulton, AJM
      Bisphosphonates in the treatment of Charcot neuroarthropathy: a double-blind randomised controlled trial

      DIABETOLOGIA
    88. Lane, JM; Khan, SN; O'Connor, WJ; Nydick, M; Hommen, JP; Schneider, R; Tomin, E; Brand, J; Curtin, J
      Bisphosphonate therapy in fibrous dysplasia

      CLINICAL ORTHOPAEDICS AND RELATED RESEARCH
    89. Schachar, NS
      An update on the nonoperative treatment of patients with metastastic bone disease

      CLINICAL ORTHOPAEDICS AND RELATED RESEARCH
    90. Lee, MV; Fong, EM; Singer, FR; Guenette, RS
      Bisphosphonate treatment inhibits the growth of prostate cancer cells

      CANCER RESEARCH
    91. Michigami, T; Ihara-Watanabe, M; Yamazaki, M; Ozono, K
      Receptor activator of nuclear factor kappa B ligand (RANKL) is a key molecule of osteoclast formation for bone metastasis in a newly developed model of human neuroblastoma

      CANCER RESEARCH
    92. Hiraga, T; Williams, PJ; Mundy, GR; Yoneda, T
      The bisphosphonate ibandronate promotes apoptosis in MDA-MB-231 human breast cancer cells in bone metastases

      CANCER RESEARCH
    93. Diamond, TH; Winters, J; Smith, A; De Souza, P; Kersley, JH; Lynch, WJ; Bryant, C
      The anti osteo porotic efficacy of intravenous pamidronate in men with prostate carcinoma receiving combined androgen blockade - A double blind, randomized, placebo-controlled crossover study

      CANCER
    94. Bunting, RW; Shea, B
      Bone metastasis and rehabilitation

      CANCER
    95. Berenson, JR; Rosen, LS; Howell, A; Parter, L; Coleman, RE; Morley, W; Dreicer, R; Kuross, SA; Lipton, A; Seaman, JJ
      Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases - A double-blind, randomized dose-response study

      CANCER
    96. Berenson, JR; Vescio, R; Henick, K; Nishikubo, C; Rettig, M; Swift, RA; Conde, F; Von Teichert, JM
      A phase I, open label, dose ranging trial of intravenous bolus zoledronic acid, a novel bisphosphonate, in cancer patients with metastatic bone disease

      CANCER CYTOPATHOLOGY
    97. Berenson, JR; Vescio, R; Henick, K; Nishikubo, C; Rettig, M; Swift, RA; Conde, F; Von Teichert, JM
      A phase I, open label, dose ranging trial of intravenous bolus zoledronic acid, a novel bisphosphonate, in cancer patients with metastatic bone disease

      CANCER
    98. Tubiana-Hulin, M; Beuzeboc, P; Mauriac, L; Barbet, N; Frenay, M; Monnier, A; Pion, JM; Switsers, O; Misset, JL; Assadourian, S; Bessa, E
      Double-blinded controlled study comparing clodronate versus placebo in patients with breast cancer bone metastases

      BULLETIN DU CANCER
    99. McCloskey, EV; Dunn, JA; Kanis, JA; MacLennan, ICM; Drayson, MT
      Long-term follow-up of a prospective, double-blind, placebo-controlled randomized trial of clodronate in multiple myeloma

      BRITISH JOURNAL OF HAEMATOLOGY
    100. Jagdev, SP; Coleman, RE; Shipman, CM; Rostami-H, A; Croucher, PI
      The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: evidence for synergy with paclitaxel

      BRITISH JOURNAL OF CANCER


ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 13/08/20 alle ore 04:59:52